Paclitaxel–gemcitabine combination (Gem/Pac)

The Paclitaxel–gemcitabine combination is a synergistic chemotherapy regimen rather than a single biological target [6, 15]. It comprises paclitaxel, a taxane that stabilizes microtubules to induce mitotic arrest, and gemcitabine, a pyrimidine nucleoside analog that inhibits DNA synthesis [3, 5]. This combination is a standard-of-care treatment for several malignancies, most notably metastatic pancreatic adenocarcinoma (often using the nanoparticle albumin-bound formulation, nab-paclitaxel) and metastatic breast cancer [11, 13, 17]. By targeting two distinct cellular processes—microtubule dynamics and nucleotide metabolism—the regimen achieves enhanced anti-tumor activity compared to monotherapy [6, 13]. The combination has been shown to improve overall survival and progression-free survival in patients with advanced disease compared to gemcitabine alone [13, 17]. Clinical efficacy is often monitored via tumor markers like CA 19-9 in pancreatic cancer, while dose-limiting toxicities include myelosuppression and peripheral neuropathy [10, 12, 17]. Research continues into optimizing the schedule of administration and identifying biomarkers, such as hENT1 or RRM1 expression, to predict patient response [1, 14].

Other names

Gem/PacGem-PacGemTaxolGemcitabine plus paclitaxelNab-paclitaxel plus gemcitabine

Paclitaxel stabilizes microtubules by binding to the beta-subunit of tubulin, leading to mitotic arrest [3, 4, 8]. Gemcitabine is a prodrug that, once activated, inhibits ribonucleotide reductase (RRM1) to deplete deoxynucleotide pools and incorporates into DNA to cause masked chain termination [5, 10, 11].